- Launch of two new high-potency cannabis cultivars, expanding Aurora Cannabis’s (ACB, Financial) product portfolio in Australia.
- IndiMed remains one of the most prescribed medical cannabis brands in the Australian market.
- Products meet TGA-GMP standards, ensuring adherence to quality and regulatory compliance.
Aurora Cannabis Inc. (NASDAQ: ACB) has announced the expansion of its medical cannabis portfolio in Australia with the introduction of IndiMed TEMPO 22 through its subsidiary, MedReleaf Australia. This initiative includes two new cultivars, Lemon Laser (Sativa) and Pickled Petrol (Indica), each characterized by a high THC concentration of 22% and less than 1% CBD, available in a 15g dried cannabis format.
IndiMed is already recognized as one of the most prescribed medical cannabis brands in Australia, and this expansion enhances Aurora’s commitment to delivering high-quality, accessible treatment options tailored to meet the diverse needs of patients. The launch reinforces the company’s strategic positioning as a leader in the global medical cannabis industry.
The introduction of these new cultivars adheres strictly to TGA-GMP standards, a testament to Aurora’s dedication to compliance and quality, thereby fortifying its presence in Australia’s steadily growing medical cannabis market.
